SEROTONIN TYPE 6 RECEPTOR ANTAGONISTS:

recent progress in sustainable synthesis methods and novel therapeutic applications

PROGRAMME

14/06/2022

	Opening session
09:45-10:00	REGISTRATION
10:00-10:05	Magdalena Sajdak , Polish Academy of Sciences – Scientific Center in Paris Welcome Speech
10:05-10:30	Frédéric Lamaty, Institut des Biomolécules Max Mousseron, University of Montpellier Gilles Subra, Institut des Biomolécules Max Mousseron, University of Montpellier Philippe Marin, Institut of Functional Genomics, ISERM Pawel Zajdel, Jagiellonian University Medical College
	Session 1: Sustainable synthetic approaches
10:30-10:55	Xavier Bantreil , Institut des Biomolécules Max Mousseron, University of Montpellier Biologically active molecules and Enabling Technologies: the Future in Motion?
10:55-11:20	Vittorio Canale , Jagiellonian University Medical College Medicinal mechanochemistry approach for a sustainable synthesis of 5-HT receptor antagonists
11:20-11:45	Ophélie Bento , Institut des Biomolécules Max Mousseron, University of Montpellier When mechanochemistry meets biology: synthesis and characterization of the pharmacological properties of 5-HT ₆ receptor ligands
11:45-12:15	COFFEE BREAK
Session 2	2: Multitargeted approaches involving 5-HT ₆ and 5-HT ₃ receptor modalities
12:15-12:40	Katarzyna Grychowska , Jagiellonian University Medical College From selective 5-HT ₆ Rs antagonists to dually-acting 5-HT ₃ /5-HT ₆ Rs antagonists: a story of 1H-pyrrolo[3,2-c]quinoline
12:40-13:05	Christophe Rochais , Centre d'Etudes et de Recherche sur le Médicament de Normandie Polypharmacology approaches directed to 5-HT ₆ Rs in Alzheimer's disease: from MTDL to pleiotropic prodrugs

13:05-13:30	Karolina Pytka , Jagiellonian University Medical College HBK-15 – a unique multimodal compound showing fast antidepressant-like and procognitive effects
13:30-15:30	LUNCH BREAK
	Session 3: Structural Biology, interactomics and signalling
15:30-15:55	Hugues Nury , Institut de Biologie Structurale, University of Grenoble Conformational transitions of a serotonin receptor and a nicotinic one
15:55-16:20	Séverine Chaumont-Dubel , Institut of Functional Genomics, ISERM <i>The 5-HT</i> ⁶ receptor in neurodevelopment: From embryo to adult, location and partners are paramount
16:20-16:45	DISCUSSION
09:15-09:30	15/06/2022 REGISTRATION
Sessi	on 4: Selective 5-HT ₆ R inverse agonists - novel therapeutic opportunities
09:30-09:55	Carine Bécamel, Institut of Functional Genomics, ISERM 5-HT ₆ receptor-operated mTOR signaling as target for disease modifiers preventing onset of cognitive deficits in schizophrenia
09:55-10:20	Christine Courteix , Université Clermont Auvergne, INSERM U1107, NEURO-DOL 5-HT ₆ R inverse agonists, a new strategy in the treatment of neuropathic pain
10:20-10:40	COFFEE BREAK
10:40-11:05	Laurent Givalois , INSERM U1198, University of Montpellier Evaluation of two 5-HT ₆ R antagonists in an acute model of Alzheimer's disease
11:05-11:30	Julie Le Merrer & Jerome Becker , INSERM U1253 "Imaging and Brain" The two faces of the 5-HT ₆ receptor in autism spectrum disorders: beneficial or deleterious
11:30-12:15	DISCUSSION & CLOSING REMARKS

12:15-14:00 LUNCH BREAK